Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

被引：674

作者：

Sacco, Ralph L. ^{[1
]}

Diener, Hans-Christoph ^{[2
]}

Yusuf, Salim ^{[4
,5
]}

Cotton, Daniel ^{[8
]}

Ounpuu, Stephanie ^{[6
]}

Lawton, William A. ^{[9
]}

Palesch, Yuko ^{[11
]}

Martin, Renee H. ^{[11
]}

Albers, Gregory W. ^{[12
]}

Bath, Philip ^{[10
]}

Bornstein, Natan ^{[13
]}

Chan, Bernard P. L. ^{[14
]}

Chen, Sien-Tsong ^{[15
]}

Cunha, Luis ^{[16
]}

Dahlof, Bjorn ^{[17
]}

De Keyser, Jacques ^{[18
]}

Donnan, Geoffrey A. ^{[19
]}

Estol, Conrado ^{[20
]}

Gorelick, Philip ^{[21
]}

Gu, Vivian ^{[22
]}

Hermansson, Karin ^{[24
]}

Hilbrich, Lutz ^{[8
]}

Kaste, Markku ^{[25
]}

Lu, Chuanzhen ^{[23
]}

Machnig, Thomas ^{[3
]}

Pais, Prem ^{[26
]}

Roberts, Robin ^{[4
]}

Skvortsova, Veronika ^{[27
]}

Teal, Philip ^{[7
]}

Toni, Danilo ^{[28
]}

VanderMaelen, Cam ^{[8
]}

Voigt, Thor ^{[8
]}

Weber, Michael ^{[29
]}

Yoon, Byung-Woo ^{[30
]}

机构：

[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[2] Univ Duisberg Essen, Essen, Germany

[3] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany

[4] McMaster Univ, Hamilton, ON, Canada

[5] Hamilton Hlth Sci, Hamilton, ON, Canada

[6] Boehringer Ingelheim GmbH & Co KG, Burlington, ON, Canada

[7] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[8] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[9] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England

[10] Univ Nottingham, Nottingham NG7 2RD, England

[11] Med Univ S Carolina, Charleston, SC 29425 USA

[12] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[13] Ichilov Hosp, Tel Aviv, Israel

[14] Natl Univ Singapore Hosp, Singapore 117548, Singapore

[15] Chang Gung Mem Hosp, Taipei 10591, Taiwan

[16] Hosp Univ Coimbra, Coimbra, Portugal

[17] Sahlgrens Univ Hosp, Gothenburg, Sweden

[18] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands

[19] Univ Melbourne, Heidelberg West, Australia

[20] Neurol Ctr Treatment & Res, Buenos Aires, DF, Argentina

[21] Univ Illinois, Chicago, IL USA

[22] Boehringer Ingelheim Shanghai Pharmaceut, Shanghai, Peoples R China

[23] Huashan Hosp, Shanghai, Peoples R China

[24] Boehringer Ingelheim GmbH & Co KG, Stockholm, Sweden

[25] Univ Helsinki, Cent Hosp, Helsinki, Finland

[26] St Johns Med Coll, Bangalore, Karnataka, India

[27] Russian State Med Univ, Moscow 117437, Russia

[28] Univ Roma La Sapienza, Rome, Italy

[29] SUNY Downstate Coll Med, New York, NY USA

[30] Seoul Natl Univ Hosp, Seoul 110744, South Korea

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2008年 / 359卷 / 12期

关键词：

D O I：

10.1056/NEJMoa0805002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens - aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. Methods: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. Results: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). Conclusions: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.).

引用

页码：1238 / 1251

页数：14

共 31 条

[1] CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].

ADAMS, HP ;

BENDIXEN, BH ;

KAPPELLE, LJ ;

BILLER, J ;

LOVE, BB ;

GORDON, DL ;

MARSH, EE ;

KASE, CS ;

WOLF, PA ;

BABIKIAN, VL ;

LICATAGEHR, EE ;

ALLEN, N ;

BRASS, LM ;

FAYAD, PB ;

PAVALKIS, FJ ;

WEINBERGER, JM ;

TUHRIM, S ;

RUDOLPH, SH ;

HOROWITZ, DR ;

BITTON, A ;

MOHR, JP ;

SACCO, RL ;

CLAVIJO, M ;

ROSENBAUM, DM ;

SPARR, SA ;

KATZ, P ;

KLONOWSKI, E ;

CULEBRAS, A ;

CAREY, G ;

MARTIR, NI ;

FICARRA, C ;

HOGAN, EL ;

CARTER, T ;

GURECKI, P ;

MUNTZ, BK ;

RAMIREZLASSEPAS, M ;

TULLOCH, JW ;

QUINONES, MR ;

MENDEZ, M ;

ZHANG, SM ;

ALA, T ;

JOHNSTON, KC ;

ANDERSON, DC ;

TARREL, RM ;

NANCE, MA ;

BUDLIE, SR ;

DIERICH, M ;

HELGASON, CM ;

HIER, DB ;

SHAPIRO, RA .

STROKE, 1993, 24 (01) :35-41

[2]

Akhtar Mateen, 2007, Congest Heart Fail, V13, P130, DOI 10.1111/j.1527-5299.2007.06047.x

[3]

[Anonymous], 2002, **DROPPED REF**

[4]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[5] Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].

Bhatt, DL ;

Fox, KAA ;

Hacke, W ;

Berger, PB ;

Black, HR ;

Boden, WE ;

Cacoub, P ;

Cohen, EA ;

Creager, MA ;

Easton, JD ;

Flather, MD ;

Haffner, SM ;

Hamm, CW ;

Hankey, GJ ;

Johnston, SC ;

Mak, KH ;

Mas, JL ;

Montalescot, G ;

Pearson, TA ;

Steg, PG ;

Steinhubl, SR ;

Weber, MA ;

Brennan, DM ;

Fabry-Ribaudo, L ;

Booth, J ;

Topol, EJ ;

Frye, RL ;

Amarenco, P ;

Brass, LM ;

Buyse, M ;

Cohen, LS ;

DeMets, DL ;

Fuster, V ;

Hart, RG ;

Marler, JR ;

McCarthy, C ;

Schoemig, A ;

Lincoff, AM ;

Brener, SJ ;

Sila, CA ;

Albuquerque, A ;

Aroutiounov, G ;

Artemiev, D ;

Atkeson, BG ;

Bartel, T ;

Basart, DCG ;

Lima, AB ;

Belli, G ;

Bordalo e Sa, AL ;

Bosch, X .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717

[6] Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis [J].

Chimowitz, MI ;

Lynn, MJ ;

Howlett-Smith, H ;

Stern, BJ ;

Hertzberg, VS ;

Frankel, MR ;

Levine, SR ;

Chaturvedi, S ;

Kasner, SE ;

Benesch, CG ;

Sila, CA ;

Jovin, TG ;

Romano, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) :1305-1316

[7] Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics [J].

D'Agostino, RB ;

Massaro, JM ;

Sullivan, LM .

STATISTICS IN MEDICINE, 2003, 22 (02) :169-186

[8] Recurrent stroke and cardiac risks after first ischemic stroke - The Northern Manhattan Study [J].

Dhamoon, MS ;

Sciacca, RR ;

Rundek, T ;

Sacco, RL ;

Elkind, MSV .

NEUROLOGY, 2006, 66 (05) :641-646

[9] Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The prevention regimen for effectively avoiding second strokes trial (PRoFESS) [J].

Diener, Hans-Christoph ;

Sacco, Ralph ;

Yusuf, Salim .

CEREBROVASCULAR DISEASES, 2007, 23 (5-6) :368-380

[10] Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial [J].

Diener, HC ;

Bogousslavsky, J ;

Brass, LM ;

Cimminiello, C ;

Csiba, L ;

Kaste, M ;

Leys, D ;

Matias-Guiv, J ;

Rupprecht, HJ .

LANCET, 2004, 364 (9431) :331-337

← 1 2 3 4 →